Norma Carmen
Gutiérrez Gutiérrez
Profesora Asociada CC. Salud
![Foto de Norma Carmen](/img/nophoto.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaHospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (11)
2024
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2022
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Blood cancer journal, Vol. 12, Núm. 4, pp. 76
2020
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2012
-
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors
EMBO Journal, Vol. 31, Núm. 18, pp. 3704-3717
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
-
Response to imatinib mesylate in patients with hypereosinophilic syndrome
International Journal of Hematology, Vol. 96, Núm. 3, pp. 320-326
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
2000
-
Two cases of myeloid disorders and a t(8;12)(q12;p13)
Haematologica, Vol. 85, Núm. 1, pp. 31-34